What's on?

Friday 24 March: World Tuberculosis Day

21 Mar 2017 - 11h42 | By INSERM PRESS OFFICE

Macrophages colonisés par Mycobacterium tuberculosis

Macrophages colonisés par Mycobacterium tuberculosis © Denis Fenistein-Priscille Brodin (Inserm)

According to WHO, tuberculosis is one of the 10 main causes of death in the world. In 2015, 10.4 million people were suffering from this illness and 1.8 million died. Furthermore, tuberculosis is the main cause of death in people who are HIV positive.

 According to WHO, a third of the world population has latent tuberculosis. In 5 to 10% of cases, the Koch bacillus (mycobacterium tuberculosis) becomes active, particularly in people whose immune systems are compromised and who have a much higher risk of developing the disease.

Faced with this major health problem, Inserm researchers are getting together to advance the research, particularly with the issue of multi-resistant strains of the agent to antibiotics.

Researchers from Inserm Unit 1019 at the Lille Centre for Infection and Immunity

(CNRS/Institut Pasteur Lille/Inserm/University of Lille) have invented a prototype drug SMARt-420 that can eliminate resistance to ethionamide, an antibiotic used to treat tuberculosis.

Read the press release “Tuberculosis and antibiotic resistance: researchers In Lille invent a new prototype drug,” published 16 March.

See the information pack on tuberculosis, devised in collaboration with Camille Locht, microbiologist and Director of the Lille Centre for Infection and Immunity, Inserm Unit 1019 (CNRS/Institut Pasteur Lille/Inserm/Lille University).

A team of researchers from the Lille Centre for Infection and Immunity (CNRS/Institut Pasteur Lille/Inserm/Lille University) and from the Institute of Systematics, Evolution and Biodiversity (CNRS/National Museum of Natural History/UPMC/EPHE) is interested in the evolutionary history of the mycobacterium responsible for tuberculosis, particularly the so-called Beijing lineage associated with the propagation of multidrug resistant TB in Eurasia.

See press release: “The origins of multi-drug resistant strains uncovered,” published 19 January 2015.

TO CITE THIS POST :
Inserm press room Friday 24 March: World Tuberculosis Day Link : http://presse.inserm.fr/en/friday-24-march-world-tuberculosis-day/27743/



Medias
Researcher Contact

Alain Baulard

Inserm Research Director

Unit 1019 Lille Centre for Infection and Immunity

+33 (0)3 20 87 11 55

alain.baulard@ibl.fr

 Nicolas Willand

Professor – Lille University

Inserm Unit 1177 “ Drugs and molecules which act on living systems”

+33 (0)3 20 96 49 91

nicolas.willand@univ-lille2.fr

Tuberculosis file

 Camille Locht

Inserm Research Director

Director of Lille Centre for Infection and Immunity 

+33 (0)3 20 87 11 51

camille.locht@pasteur-lille.fr

Multi-drug resistant tuberculosis in Eurasia

Philip Supply

Unit 1019 Lille Centre for Infection and Immunity

+33 (0)3 20 87 11 54

Philip.supply@ibl.fr

Thierry Wirth

Unit 1019 Lille Centre for Infection and Immunity

+33 (0)1 40 79 80 36

Wirth@mnhn.fr

 

fermer
fermer
RSS Youtube